Brokerages expect Tricida Inc (NASDAQ:TCDA) to report earnings of ($0.87) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Tricida’s earnings. The lowest EPS estimate is ($0.88) and the highest is ($0.85). Tricida reported earnings of ($0.58) per share during the same quarter last year, which would indicate a negative year over year growth rate of 50%. The company is scheduled to report its next earnings results on Wednesday, August 14th.
On average, analysts expect that Tricida will report full-year earnings of ($3.44) per share for the current fiscal year, with EPS estimates ranging from ($3.47) to ($3.40). For the next year, analysts forecast that the company will post earnings of ($3.59) per share, with EPS estimates ranging from ($3.82) to ($3.35). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Tricida.
Tricida (NASDAQ:TCDA) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10).
A number of brokerages have weighed in on TCDA. Needham & Company LLC began coverage on shares of Tricida in a report on Friday, May 24th. They issued a “buy” rating and a $50.00 price target for the company. Zacks Investment Research downgraded shares of Tricida from a “buy” rating to a “hold” rating in a report on Thursday, April 11th. Finally, Empire increased their price target on shares of Tricida from $37.00 to $58.00 in a report on Monday, April 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $44.33.
In other news, insider Claire Lockey sold 13,494 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $25.01, for a total value of $337,484.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Dawn Parsell Otto sold 2,500 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $25.02, for a total transaction of $62,550.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 133,822 shares of company stock valued at $4,005,214. Insiders own 66.70% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. Parametric Portfolio Associates LLC raised its stake in shares of Tricida by 2.7% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,998 shares of the company’s stock valued at $425,000 after buying an additional 292 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Tricida by 8.4% in the 1st quarter. Wells Fargo & Company MN now owns 9,847 shares of the company’s stock valued at $381,000 after buying an additional 767 shares in the last quarter. Barclays PLC raised its stake in shares of Tricida by 14.4% in the 4th quarter. Barclays PLC now owns 7,176 shares of the company’s stock valued at $169,000 after buying an additional 906 shares in the last quarter. Quantamental Technologies LLC acquired a new position in shares of Tricida in the 1st quarter valued at $39,000. Finally, Marshall Wace North America L.P. raised its stake in shares of Tricida by 99.0% in the 1st quarter. Marshall Wace North America L.P. now owns 2,591 shares of the company’s stock valued at $100,000 after buying an additional 1,289 shares in the last quarter. Institutional investors own 62.89% of the company’s stock.
Shares of Tricida stock opened at $36.74 on Friday. The company has a quick ratio of 8.30, a current ratio of 8.30 and a debt-to-equity ratio of 0.24. Tricida has a fifty-two week low of $19.43 and a fifty-two week high of $40.83. The firm has a market capitalization of $1.81 billion and a price-to-earnings ratio of -7.92.
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Further Reading: Technical Indicators – What is a Golden Cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.